EGFR and colorectal cancer: Saltz Saltz LB LB Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J. Clin.